However, current clinical studies have not shown expected results with anti‐VEGFR drugs in the treatment of ACC, including Lenvatinib [42, 43, 44], Axitinib [45], and Sorafenib [46, 47]. The gene discussed is KDR; the disease is adrenal cortex carcinoma.